INC Research, a therapy-focused CRO, has broadened its services around Medidata Solutions' clinical cloud platform by attaining three new accreditations.

Now offering implementation and management services for Medidata Balance, Medidata Rave Targeted SDV and Medidata Coder, INC Research is expanding its ability to help research sponsors overcome critical cost, risk and efficiency challenges across the clinical chain.  

In 2006, INC Research became one of the first CROs to join Medidata's Partner Program and has since conducted more than 100 study builds for the Medidata Rave electronic data capture (EDC) and clinical data management (CDM) system. The company achieved its first Medidata accreditation for Rave in 2007, and with these three new accreditations, introduced in December 2011, INC Research now holds more accreditations than any other Medidata Services Partner.

"We've had great success as a Medidata Services Partner, and are very excited to expand our collaboration to offer our customers more options, further distinguish ourselves from the competition and help drive our future growth," said Jamie Macdonald, chief operating officer, INC Research. "More and more sponsors are looking to improve operational efficiencies that platforms like Medidata Rave can offer." 

With Medidata Balance accreditation, INC Research enables sponsors and investigators to use one system—Medidata Rave—for patient data capture, randomization and trial supply management activities. Medidata Rave Targeted SDV allows INC Research to provide more efficient site monitoring services by executing targeted (risk-based) source document verification, while Medidata Coder allows INC Research to provide enhanced medical coding.

Macdonald added, "We're also excited about Balance's ability to offer both block and dynamic allocation randomization methods, and streamline sponsors' supply management processes." 

INC Research has already begun using all three solutions with joint Medidata customers and will expand to new trials in coming months.